December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Biocorrx Inc (OP:BICX)

0.3052 UNCHANGED
Streaming Delayed Price Updated: 10:54 AM EST, Dec 23, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 0.3052
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 0.3052
Today's Range 0.3052 - 0.3052
52wk Range 0.2044 - 1.450
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
BioCorRx Provides Update on OTC Markets Quotation Status and Planned Form S1 Filing
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Regulatory Compliance
BioCorRx Provides Update on OTC Markets Quotation Status and Planned Form S1 Filing
Via TheNewswire.com
Topics Regulatory Compliance

Performance

YTD
-25.6%
-25.6%
1 Month
-4.6%
-4.6%
3 Month
-23.7%
-23.7%
6 Month
-15.2%
-15.2%
1 Year
-19.7%
-19.7%

More News

Read More
News headline image
BioCorRx Inc. to Present at the Life Sciences Virtual Investor Forum December 11th
From Virtual Investor Conferences; BioCorRx Inc.
Via GlobeNewswire
News headline image
Life Sciences Virtual Investor Forum Agenda Announced for December 11th
From Virtual Investor Conferences
Via GlobeNewswire
BioCorRx, Inc. Announces Q3 2025 Results: Second Straight Quarter of Meaningful Revenue Driven by LUCEMYRA(R) Acquisition
Via TheNewswire.com
News headline image
BioCorRx, Inc. Announces Q3 2025 Results: Second Straight Quarter of Meaningful Revenue Driven by LUCEMYRA(R) Acquisition
Via NewMediaWire
News headline image
BioCorRx Reports 3,985% Revenue Growth to $313K in the First Half of 2025 Driven by LUCEMYRA(R) (lofexidine) Sales
Via NewMediaWire
Topics Death
BioCorRx Reports 3,985% Revenue Growth to $313K in the First Half of 2025 Driven by LUCEMYRA(R) (lofexidine) Sales
Via TheNewswire.com
Topics Death
News headline image
BioCorRx Reports Business Update for the First Quarter of 2025
Via NewMediaWire
Topics Death
BioCorRx Reports Business Update for the First Quarter of 2025
Via TheNewswire.com
Topics Death
News headline image
BioCorRx Pharmaceuticals Inc. Announces That it has Acquired LUCEMYRA(R) (lofexidine), an FDA-Approved Opioid Withdrawal Medication, From USWM, LLC
Via NewMediaWire
BioCorRx Pharmaceuticals Inc. Announces That it has Acquired LUCEMYRA(R) (lofexidine), an FDA-Approved Opioid Withdrawal Medication, From USWM, LLC
Via TheNewswire.com
News headline image
BioCorRx Reports Business Update for the Second Quarter of 2024
Via NewMediaWire
Topics Intellectual Property
News headline image
BioCorRx Reports Business Update for the First Quarter of 2024
Via NewMediaWire
Topics Death Intellectual Property
BioCorRx Reports Business Update for the First Quarter of 2024
Via TheNewswire.com
Topics Death Intellectual Property
News headline image
BioCorRx Pharmaceuticals Inc. Awarded New Patent for Novel Compound to Treat Pain, Depression, and Schizophrenia
Via NewMediaWire
Topics Intellectual Property
BioCorRx Pharmaceuticals Inc. Awarded New Patent for Novel Compound to Treat Pain, Depression, and Schizophrenia
Via TheNewswire.com
Topics Intellectual Property
News headline image
BioCorRx Reports Business Update for 2023
Via NewMediaWire
Topics Death
BioCorRx Reports Business Update for 2023
Via TheNewswire.com
Topics Death
BioCorRx Pharmaceuticals Inc. Awarded NIDA Grant of Approximately $11 million Over Three Years for Research on BICX104, a Naltrexone Implant in Combination with Bupropion for the Treatment of MUD
Via NewMediaWire
BioCorRx Pharmaceuticals Inc. Awarded NIDA Grant of Approximately $11 million Over Three Years for Research on BICX104, a Naltrexone Implant in Combination with Bupropion for the Treatment of MUD
Via TheNewswire.com
Topics Death
News headline image
BioCorRx Pharmaceuticals Inc. Appoints Neuroscientist Dr. Kate DeVarney to the Board of Directors
Via NewMediaWire
BioCorRx Pharmaceuticals Inc. Appoints Neuroscientist Dr. Kate DeVarney to the Board of Directors
Via TheNewswire.com
News headline image
Collective Audience And 3 Other Stocks Under $1 Insiders Are Buying ↗
Via Benzinga
Topics Stocks
News headline image
BioCorRx Appoints Renowned Investment and Capital Markets Executive Louis Lucido as President
Via NewMediaWire

Frequently Asked Questions

Is Biocorrx Inc publicly traded?
Yes, Biocorrx Inc is publicly traded.
What exchange does Biocorrx Inc trade on?
Biocorrx Inc trades on the OTC Traded
What is the ticker symbol for Biocorrx Inc?
The ticker symbol for Biocorrx Inc is BICX on the OTC Traded
What is the current price of Biocorrx Inc?
The current price of Biocorrx Inc is 0.3052
When was Biocorrx Inc last traded?
The last trade of Biocorrx Inc was at 12/23/25 10:54 AM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.